F0175000
Flucytosine
European Pharmacopoeia (EP) Reference Standard
Synonym(s):
5-Fluorocytosine, 4-amino-5-fluoro-2(1H)-pyrimidinone, Flucytosine
Sign Into View Organizational & Contract Pricing
All Photos(1)
About This Item
Empirical Formula (Hill Notation):
C4H4FN3O
CAS Number:
Molecular Weight:
129.09
Beilstein/REAXYS Number:
127285
MDL number:
UNSPSC Code:
41116107
PubChem Substance ID:
NACRES:
NA.24
Recommended Products
grade
pharmaceutical primary standard
API family
flucytosine
manufacturer/tradename
EDQM
mp
298-300 °C (dec.) (lit.)
application(s)
pharmaceutical (small molecule)
format
neat
storage temp.
2-8°C
SMILES string
NC1=NC(=O)NC=C1F
InChI
1S/C4H4FN3O/c5-2-1-7-4(9)8-3(2)6/h1H,(H3,6,7,8,9)
InChI key
XRECTZIEBJDKEO-UHFFFAOYSA-N
Looking for similar products? Visit Product Comparison Guide
General description
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.
Application
Flucytosine EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.
Biochem/physiol Actions
Nucleoside analog that has antifungal activities. 5-FC is deaminated by cytosine deaminase to product 5-fluorouracil, resulting in RNA miscoding. 5-Fluorocytosine inhibits DNA and RNA synthesis and interferes with ribosomal protein synthesis.
Packaging
The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.
Other Notes
Sales restrictions may apply.
related product
Choose from one of the most recent versions:
Certificates of Analysis (COA)
Lot/Batch Number
Sorry, we don't have COAs for this product available online at this time.
If you need assistance, please contact Customer Support.
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Customers Also Viewed
Nese Karaaslan Biyikli et al.
Pediatric nephrology (Berlin, Germany), 19(7), 801-804 (2004-06-03)
Bilateral fungal obstruction of the renal collecting system is rare in infancy. Treatment options include medical or surgical procedures. Reports of successful medical treatment with liposomal amphotericin B have been published but the duration of treatment is controversial. We report
R Patel
Mayo Clinic proceedings, 73(12), 1205-1225 (1998-12-30)
Traditionally, amphotericin B has been the cornerstone of antifungal treatment. Toxicity, however, is a major dose-limiting factor of amphotericin B deoxycholate. Nevertheless, it continues to have a major role in the treatment of deep-seated mycotic infections. Recently, less nephrotic lipid
A Polak
Annales de biologie clinique, 45(6), 669-672 (1987-01-01)
The antimycotic and pharmacological properties of 5-fluorocytosine are presented. Especially the aspect of good gastrointestinal absorption, elimination by the kidney, unwanted side effects and appearance of primary and secondary resistance are discussed. The indication of 5 FC monotherapy or combination
[Flucytosine - a classical partner for combination therapy].
Annemarie Polak
Mycoses, 45 Suppl 3, 31-33 (2003-04-15)
W L Whelan
Critical reviews in microbiology, 15(1), 45-56 (1987-01-01)
In terms of genetically determined susceptibility to the clinical antifungal agent 5-fluorocytosine (5-FC), Candida albicans may be homozygous sensitive (FCY/FCY), homozygous resistant (fcy/fcy), or heterozygous (fcy/FCY). Although heterozygotes are only slightly resistant, they occur at significant frequency among clinical strains
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service